BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells
Publication
, Journal Article
J Devor, E; E Thomas, A; M Schickling, B
Published in: Journal of Cancer Science and Clinical Therapeutics
2023
Duke Scholars
Published In
Journal of Cancer Science and Clinical Therapeutics
DOI
EISSN
2637-5079
Publication Date
2023
Volume
07
Issue
02
Publisher
Fortune Journals
Citation
APA
Chicago
ICMJE
MLA
NLM
J Devor, E., E Thomas, A., & M Schickling, B. (2023). BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells. Journal of Cancer Science and Clinical Therapeutics, 07(02). https://doi.org/10.26502/jcsct.5079197
J Devor, Eric, Ariane E Thomas, and Brandon M Schickling. “BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells.” Journal of Cancer Science and Clinical Therapeutics 07, no. 02 (2023). https://doi.org/10.26502/jcsct.5079197.
J Devor E, E Thomas A, M Schickling B. BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells. Journal of Cancer Science and Clinical Therapeutics. 2023;07(02).
J Devor, Eric, et al. “BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells.” Journal of Cancer Science and Clinical Therapeutics, vol. 07, no. 02, Fortune Journals, 2023. Crossref, doi:10.26502/jcsct.5079197.
J Devor E, E Thomas A, M Schickling B. BRCA2 Status Alters the Effect of the P53 Reactivator HO-3867 in Ovarian Cancer Cells. Journal of Cancer Science and Clinical Therapeutics. Fortune Journals; 2023;07(02).
Published In
Journal of Cancer Science and Clinical Therapeutics
DOI
EISSN
2637-5079
Publication Date
2023
Volume
07
Issue
02
Publisher
Fortune Journals